Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Kristin Cavallari was the teen queen bee of 'Laguna Beach.' Now she's a 'cringey' mom. - 2vote in favor of Your #1 kind of climate
- 3Lift Your Style: Famous Hairdos for Ladies
- 4Iconic iceberg turns blue, on verge of totally disintegrating, NASA says
- 5Ukrainian man arrested in Germany on suspicion of spying for Russia
- Israel faces tough choices over haredi draft exemptions, legal expert warns
- German diesel hits new records over Easter weekend
- Change Your Home into an Exercise center with These Famous Wellness Gadgets
- Allow Innovative Progressions To have a Tremendous Effect
- Poland Crypto Bill Clears Sejm Again, Defying President — Will “Restrictive” Rules Stick?
- Opening Potential: Self-awareness and Long lasting Learning
- Italy now recognizes the crime of femicide and punishes it with life in prison
- Air Canada CEO To Resign After Backlash—Here’s Why Communication Skills Is Now A Leadership Requirement
- China’s new condom tax will prove no effective barrier to country’s declining fertility rate
